7:25 am Coffee & Badge Collection
Synopsis
Join us for light breakfast refreshments and coffee
8:25 am Chair’s Opening Remarks
Segmenting Patients in Multifactorial Heterogeneous Disease Populations to Pioneer a Precision Medicine Approach
8:30 am The Cutaneous Immune System in the Functional Endotyping of Th2high/low & IL-31 Responses in Atopic Dermatitis Patients.
Synopsis
- Exploring the underlying mechanisms that cause dermatological diseases to gain a better understanding of the disease pathology and how this influences differential disease phenotypes and endotypes
- How many pathways play a role in dermatological diseases, are each of these a separate mechanism with therapeutic opportunity? Is this what contributes to differential diseases presentation?
9:00 am AI Assisted Objective Skin Imaging & Analysis of Skin Diseases & Drug Effects in Clinical Trials
Synopsis
- Standardized high quality mobile skin imaging
- Smart skin imaging data and objective image analysis
- Machine learning and AI powered decision support in trials and new digital skin biomarker and endpoints in HS and beyond
9:30 am Panel Discussion: Segmenting Heterogeneous Patient Populations into Clinically Relevant Subgroups to Improve Therapeutic Outcomes
Synopsis
- Exploring the effects of variability in disease presentation and response to treatment
- Understanding strategies for segmenting patient populations into clinically relevant subgroups based on demographic, clinical, and genetic factors using genotyping techniques
- Examining the visibility for both large pharma and smaller biotech and assessing benefits and costs
10:00 am Speed Networking
Synopsis
This session is the perfect opportunity to get face-to-face time with the key opinion leaders in the dermatology drug development industry. Establish meaningful connections to build upon for the rest of the conference and gain individual insight into the pioneering research and therapeutic development in the space.
10:40 am Morning Break
Translational Track
Exploring Permeability Models, Non- Invasive Assessments & Advanced Formulation Techniques
11:00 am Exploring Non-Invasive Assessments of Skin Penetration of Molecules with Biomarker Fingerprinting
Synopsis
- Investigating the use of biomarkers as unique indicators to assess the penetration of molecules into the skin
- Creating target engagement profiles of molecules to ensure molecule is active through formulation development
- Determining penetration of a large numbers of molecules through the skin simultaneously
11:30 am The Benefits of Rational Design in Topical Formulation Development
Synopsis
- Topical formulations are often complex, but the underlying physics and chemistry can be generally understood
- Rational design of formulations and analytical methods enables efficient development and de-risking
- Judgement and decision making are critical in topical formulation development
11:40 am Overcoming the Unreliability of Preclinical Models of Dermatological Disease to Reduce Efficacy Data Failure
Synopsis
- Generating meaningful disease models without a clear understanding of disease pathophysiology
- Novel models which accurately recapitulate human skin and accurately reflect in vivo conditions to bridge the translational gap
Clinical Track
Strategizing Clinical Trials Design to Improve Clinical Outcomes
11:00 am Demonstrating Efficacy in Clinical Trials with Novel & Meaningful Endpoints
Synopsis
- Exploring why the HiSCR score is not the most clinically meaningful endpoint in HS
- Investigating variance across trials and examine the reproducibility of endpoints
- Identifying the opportunities associated with using innovative endpoints to evaluate the effectiveness of new dermatological treatments
11:30 am Enhancing Objectivity in Dermatology Trials with Photography
Synopsis
- Photography best practices 0 Imaging endpoints: extracting data to support your claims
- Case studies (real-world examples)
11:45 am Utilizing the Skin Transcriptome as a Tool for Biomarker Profiling and Measurements of Efficacy
Synopsis
- Exploring MADAD transcriptome, a gene signature for key pathways of AD to evaluate therapeutic responses
- Showing the clinical efficacy of RAPT193 with improved MADAD transcriptome
- Utilizing the skin transcriptome beyond CCR4 antagonism
12:15 pm Lunch Break and Networking
Divulging Dermatology Disease Drivers to Harness Novel Targets
1:30 pm Development of a Novel Oral Peptide Therapy to Target the IL-23 Receptor in IL-23-Mediated Diseases
Synopsis
- Combining high potency with gastrointestinal stability provides an approach to overcome typically low systemic bioavailability of peptide therapeutics administered orally
- Targeting the IL-23 pathway with an oral peptide that binds the IL-23 receptor has the potential to be a first-in-class therapy for psoriasis and other IL-23-mediated diseases
2:00 pm Epoxytiglianes for the Treatment of Dermatological Lesions & Chronic Wounds
Synopsis
- The epoxytiglianes are a family of diterpene esters with a multifactorial mode of action, currently being developed as therapeutics to treat a range of dermatological indications
- Emerging data suggest that our current clinical candidates (Tigilanol Tiglate and EBC-1013) directly affect the survival of both neoplastic cells and bacteria/associated biofilms, in addition to inducing an acute but rapidly resolving inflammatory response in skin resident/migratory cell types that resets the wound microenvironment and facilitates healing with minimal scarring
- Early clinical data and case studies illustrate the potential clinical utility and patient benefits of the epoxytigliane drug class
2:10 pm Exploring Disease Pathomechanism to Harness Promising Novel Targets
Synopsis
- Increasing understanding of disease mechanisms to unveil alternative inhibitory targets
- Exploring Neutrophil Extracellular Traps ‘NETosis’ role in Hidradenitis Suppurativa
- Shifting focus to novel treatment paradigms and positioning novel targets alongside competitors
2:40 pm Understanding Drivers of Disease Pathophysiology to Better Understand Disease Presentation
Synopsis
- Increasing understanding of underlying drivers of disease pathophysiology and how they contribute to different disease presentations
- Exploring disease pathophysiology and commonalities to develop a single therapeutic with multiple therapeutic uses
- Utilizing cGAS as a target with multiple therapeutic uses for pro-inflammatory diseases such as lupus and dermatomyositis
3:10 pm Targeting Cellular Stress Response in Dermatology – the Emergence of PARP14 as a Novel Drug Target to Treat Th2/Th17-Mediated Inflammation
Synopsis
- PARPs or ARTs are stress-induced enzymes, and their cellular function can get corrupted in disease
- Evolution of PARP14 as a promising target in Atopic Dermatitis with differentiated MOA
- RBN-3143, a clinical-stage PARP14 inhibitor, is an oral alternative to biologics foe a target that shows restricted expression in inflammatory lesions
Strategizing Clinical Trials Design to Improve Clinical Outcomes
1:30 pm Lessons Learnt from Optimizing Clinical Trials in Rare Dermatological Disease
Synopsis
- Patient as decision maker in rare disease, the role of patient advocacy and social media
- Natural History development for the assessment of efficacy, a case study of natural history development in EB
- Regulatory and Payor understanding of dermatological conditions
2:00 pm Elevating Biomarker Discovery in Clinical Trials – Combining the Versatility of Tape Stripping with the Power of Multi-omics Analyses
Synopsis
- Non-invasive skin sampling as an asset in dermatology clinical trials – evaluating the data collection opportunities
- Improving the patient experience with non-invasive alternatives to biopsy
- Using multi-omics approaches in biomarker discovery for a more comprehensive understanding of skin conditions
2:10 pm Regulatory Pathway Case Studies to Gain Phase 2 Approval Using Known Products for New Indications
Synopsis
- Repurposing products for new indications with minimal capital investment
- Detailing the process of taking existing pools of data combined with phase 1 safety data to create a regulatory filing
- Discussing the benefits of this approach in minimizing costs and minimising risk
2:40 pm Incorporating Patient Reported Outcomes in Clinical Trial Design to Foster a Patient Centric Approach
Synopsis
- Exploring incorporation of patient reported outcomes to capture patient perspectives generating more meaningful outcomes
- Increasing patient retention with a patient-centric approach to improve patient experiences
- The benefits of utilization of hybrid and decentralized clinical trials in dermatology
3:10 pm Decoding Precision Medicine in Dermatology to Determine Which Patients are Right for Which Drugs
Synopsis
- Exploring the tools and techniques that enable us to segment patients effectively
- Unravelling clinical heterogeneity through phenotypic characterization for clinical stratification
- Utilizing targeted patient segmentation to pioneer personalized care, improving therapeutic outcomes and enhancing the lives of patients
3:40 pm Afternoon Break
Decoding the Future of Dermatology
4:00 pm Advancing Clinical Research in Dermatology with Real-World Data Networks and AI
Synopsis
- Activating site networks for site and patient recruitment
- Applying AI and large language models to find patients, understand feasibility, and generate actionable insights
- Using technology to automate data collection, scale research with less burden, and fill evidence gaps
4:30 pm From Proof of Mechanism to Proof of Concept in Early Clinical Drug Development
Synopsis
- Biomarker guided drug development
- Objective and sensitive methods for dermatological drug development
- Case studies of successful proof of mechanism in patients
5:00 pm Panel Discussion: What are the Future Applications of Dermatological Drugs; What Will the Landscape Look Like in 5 Years’ Time?
Synopsis
- Key topics will cover whether more companies will look to utilize observable changes in disease progression and treatment as a springboard to other therapeutic areas.
- Set the scene for where the industry will be going next; is there enough investment in the space to sustain innovation?
- Are precision medicine and remittive therapies a promising idea or an unachievable goal?
5:30 pm Chair’s Closing Remarks & End Of Day One
5:35 pm Poster Session & Happy Hour
Synopsis
Join us at this informal session designed to connect you with your peers in a relaxed atmosphere. Continue to build and develop new and existing relationships. Explore a range of poster presentations on exciting advancements in dermatological drug development whilst showcase your own developments! Get ready to be impressed.